Targeting the mast cell in asthma

Current Opinion in Pharmacology

Volumn 5, Issue 3 SPEC. ISS., 2005, Pages 251-256

  Peachell, Peter ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CXCR3; CROMOGLYCATE DISODIUM; FC RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; ISOBUTYLMETHYLXANTHINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEDOCROMIL; OMALIZUMAB; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN KINASE SYK INHIBITOR; ROFLUMILAST; SALBUTAMOL; SALMETEROL; STEM CELL FACTOR; STEROID; THEOPHYLLINE; TOLL LIKE RECEPTOR;

ARTICLE; ASTHMA; BREATHING MUSCLE; BRONCHOSPASM; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL MATURATION; CELL SURVIVAL; CHEMOTAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; DRUG TARGETING; HUMAN; MAST CELL; MEDIATOR RELEASE; MOUSE; MUSCLE RELAXATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

EID: 18744396140     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.03.001     Document Type: Review

References (56)

1. S.T. Holgate C. Hardy C. Robinson R.M. Agius P.H. Howarth The mast cell as a primary effector cell in the pathogenesis of asthma J Allergy Clin Immunol 77 1986 274-282
2. C.M.M. Williams S.J. Galli The diverse potential effector and immunoregulatory roles of mast cells in allergic disease J Allergy Clin Immunol 105 2000 847-859
3. S.T. Holgate M. Peters-Golden R.A. Panettieri W.R. Henderson Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling J Allergy Clin Immunol 111 2003 S18-S36
4. J.A. Elias Z. Zhou G. Chupp R.J. Homer Airway remodeling in asthma J Clin Invest 104 1999 1001-1006
5. M. Wills-Karp C.L. Karp Eosinophils in asthma: Remodeling a tangled tale Science 305 2004 1726-1728
6. C.E. Brightling P. Bradding F.A. Symon S.T. Holgate A.J. Wardlaw I.D. Pavord Mast-cell infiltration of airway smooth muscle in asthma N Engl J Med 346 2002 1699-1705
7. D.S. Robinson The role of the mast cell in asthma: Induction of airway hyperresponsiveness by interaction with smooth muscle? J Allergy Clin Immunol 114 2004 58-65
8. B. Waldeck β-adrenoceptor agonists and asthma - 100 years of development Eur J Pharmacol 445 2002 1-12
9. P.J. Barnes Effect of b-agonists on inflammatory cells J Allergy Clin Immunol 104 1999 S10-S17
10. L.K. Chong R. Chess-Williams P.T. Peachell Pharmacological characterisation of the β-adrenoceptor expressed by human lung mast cells Eur J Pharmacol 437 2002 1-7
11. A.-M. Scola L.K. Chong R. Chess-Williams P.T. Peachell Influence of agonist intrinsic activity on the desensitisation of β2-adrenoceptor-mediated responses in mast cells Br J Pharmacol 143 2004 71-80
12. B.J. O'Connor S.L. Aikman P.J. Barnes Tolerance to the nonbronchodilator effects of inhaled β2-agonists in asthma N Engl J Med 327 1992 1204-1208
13. L.K. Chong P.T. Peachell β-adrenoceptor reserve in human lung: A comparison between airway smooth muscle and mast cells Eur J Pharmacol 378 1999 115-122
14. D.B. Allen L. Bielory H. Derendorf R. Dluhy G.L. Colice S.J. Szefler Inhaled corticosteroids: Past lessons and future issues J Allergy Clin Immunol 112 2003 S1-S40
15. R.P. Schleimer E.S. Schulman D.W. MacGlashan S.P. Peters E.C. Hayes G.K. Adams L.M. Lichtenstein N.F. Adkinson Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells J Clin Invest 71 1983 1830-1835
16. S. Finotto Y.A. Mekori D.D. Metcalfe Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: In vitro and in vivo evidence in murine systems J Clin Invest 99 1997 1721-1728
17. A.A. Irani G. Nilsson L.K. Ashman B. Schwartz Dexamethasone inhibits the development of mast cells from dispersed human fetal liver cells cultured in the presence of recombinant human stem cell factor Immunology 84 1995 72-78
18. J.J. Costa G.D. Demetri T.J. Harrist A.M. Dvorak D.F. Hayes E.A. Merica D.M. Menchaca A.J. Gringeri L.B. Schwartz S.J. Galli Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo J Exp Med 183 1996 2681-2686
19. S.C. Bischoff C.A. Dahinden c-kit ligand: A unique potentiator of mediator release by human lung mast cells J Exp Med 175 1992 237-244
20. M.K. Church J. Hiroi Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol Br J Pharmacol 90 1987 421-429
21. K.B.P. Leung K.C. Flint J. Brostoff B.N. Hudspith N. McI Johnson H.Y.A. Lau W.L. Liu F.L. Pearce Effects of sodium cromoglycate and nedocromil sodium on histamine secretion from human lung mast cells Thorax 43 1988 756-761
22. S.S. Saini D. MacGlashan How IgE upregulates the allergic response Curr Opin Immunol 14 2002 694-697
23. K. Asai J. Kitaura Y. Kawakami N. Yamagata M. Tsai D.P. Carbone F.T. Liu S.J. Galli T. Kawakami Regulation of mast cell survival by IgE Immunity 14 2001 791-800
24. J. Kalesnikoff M. Huber V. Lam J.E. Damen J. Zhang R.P. Siraganian G. Krystal Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival Immunity 14 2001 801-811
25. J. Kitaura J. Song M. Tsai K. Asai M. Maeda-Yamamoto A. Mocsai Y. Kawakami F-T. Liu C.A. Lowell B.G. Barisas et al. Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcεRI Proc Natl Acad Sci USA 100 2003 12911-12916
26. Chang TW: The pharmacological basis of anti-IgE therapy. Nature Biotech 18:157-162.
27. R. Djukanovic S.J. Wilson M. Kraft N.N. Jarjour M. Steel K.F. Chung W. Bao A. Fowler-Taylor J. Matthews W.W. Busse et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma Am J Respir Crit Care Med 170 2004 583-593
28. L.A. Beck G.V. Marcotte D. MacGlashan A. Togias S. Saini Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function J Allergy Clin Immunol 114 2004 527-530
29. S.T. Holgate Adenosine: A key effector molecule of asthma or just another mediator? Am J Physiol Lung Cell Mol Physiol 282 2002 167-168
30. R. Polosa W.H. Ng N. Crimi C. Vancheri S.T. Holgate M.K. Church A. Mistretta Release of mast cell-derived mediators after endobronchial adenosine challenge in asthma Am J Respir Crit Care Med 151 1995 624-629
31. E. Huszar G. Vass E. Vizi Z. Csoma E. Barat G. Molnar-Vilagos I. Herjavecz I. Horvath Adenosine in exhaled breath condensate in healthy volunteers and patients with asthma Eur Respir J 20 2002 1-6
32. J.R. Fozard The case for a role for adenosine in asthma: Almost convincing? Curr Opin Pharmacol 3 2003 264-269
33. I. Feoktistov R. Polosa S.T. Holgate I. Biaggioni Adenosine A2B receptors: A novel therapeutic target in asthma? Trends Pharmacol Sci 19 1998 148-153
34. M.R. Blackburn Too much of a good thing: Adenosine-deaminase-deficient mice Trends Pharmacol Sci 24 2003 66-70
35. J.R. Fozard J.P. Hannon Species differences in adenosine receptor-mediated bronchoconstrictor responses Clin Exp Allergy 30 2000 1213-1220
36. C.J. Meade L. Worall D. Hayes U. Protin Induction of interleukin 8 release from the HMC-1 mast cell line: Synergy between stem cell factor and activators of the adenosine A2b receptor Biochem Pharmacol 64 2002 317-325
37. I. Feoktistov E.M. Garland A.E. Goldstein D. Zeng L. Belardinelli J.N. Wells I. Biaggioni Inhibition of human mast cell activation with the novel selective adenosine A2B receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX) Biochem Pharmacol 62 2001 1163-1173
38. M. Conti W. Richter C. Mehats G. Livera J.-Y. Park C. Jin Cyclic AMP-specific phosphodiesterases as critical components of cyclic AMP signaling J Biol Chem 278 2003 5493-5496
39. J.E. Souness D. Aldous C. Sargent Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors Immunopharmacology 47 2000 127-162
40. M.C. Weston N. Anderson P.T. Peachell Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function Br J Pharmacol 121 1997 287-295
41. P. Jeffery Phosphodiesterase4-selective inhibition: Novel therapy for the inflammation of COPD Pulm Pharmacol Ther 18 2005 9-17
42. N.W. Lukacs A.L. Miller C.M. Hogaboam Chemokine receptors in asthma: searching for the correct immune targets J Immunol 171 2003 11-15
43. I. Sabroe R.C. Read M.K.B. Whyte D.H. Dockrell S.N. Vogel S.K. Dower Toll-like receptors in health and disease: Complex questions remain J Immunol 171 2003 1630-1635
44. P.J. Barnes New dugs for asthma Nat Rev Drug Discov 3 2004 831-844
45. P. Forsythe A.D. Befus CCR3, a key to mast cell phenotypic and functional diversity? Am J Respir Cell Mol Biol 28 2003 405-409
46. Brightling C.E. Ammit A.J. Kaur D. Black J.L. Wardlaw A.J. Hughes J.M. Bradding P.: The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. Am J Respir Crit Care Med, in press.
47. D. Miyazaki T. Nakamura M. Toda K.-W. Cheung-Chau R.M. Richardson S.J. Ono Macrophage inflammatory protein-1α as a co-stimulatory signal for mast cell-mediated immediate hypersensitivity reactions J Clin Invest 115 2005 434-442
48. K.S. Price D.S. Friend E.A. Mellor N. De Jesus G.F.M. Watts J.A. Boyce CC chemokine receptor 3 mobilizes to the surface of human mast cells and potentiates immunoglobulin E-dependent generation of interleukin 13 Am J Respir Cell Mol Biol 28 2003 420-427
49. S. Varadaradjalou F. Feger N. Thieblemont N.B. Hamouda J.-M. Pleau M. Dy M. Arock Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells Eur J Immunol 33 2003 899-906
50. J.D. McCurdy T.J. Olynych L.H. Maher J.S. Marshall Cutting Edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells J Immunol 170 2003 1625-1629
51. A.P. Bieneman K.L. Chichester Y.-H. Chen J.T. Schroeder Toll-like receptor 2 ligands activate human basophils for both IgE-dependent and IgE-independent secretion J Allergy Clin Immunol 115 2005 295-301
52. R.P. Siraganian J. Zhang K. Suzuki K. Sada Protein tyrosine kinase Syk in mast cell signaling Mol Immunol 38 2002 1229-1233
53. S.E. Lavens-Phillips D.W. MacGlashan The tyrosine kinases p53/56lyn and p72syk are differentially expressed at the protein level but not at the messenger RNA level in nonreleasing human basophils Am J Respir Cell Mol Biol 23 2000 566-571
54. C.L. Kepley L. Youssef R.P. Andrews B.S. Wilson J.M. Oliver Syk deficiency in nonreleaser basophils J Allergy Clin Immunol 104 1999 279-284
55. W.S.F. Wong K.P. Leong Tyrosine kinase inhibitors: A new approach for asthma Biochim Biophys Acta 1697 2004 53-69
56. U. Blank J. Rivera The ins and outs of IgE-dependent mast cell exocytosis Trends Immunol 25 2004 266-273